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The impact of malaria chemoprophylaxis
on the immune status of Africans
B. M. GREENWOOD1
The small number of studies undertaken so far indicates that malaria control with
chemoprophylaxis depresses serum gamma-globulin levels and interferes with the develop-
ment of the malaria antibodies detected by standard serological tests. Whether these
serological changes are associated with defective development of clinical immunity has
yet to be clearly established.
Chemoprophylaxis for high-risk groups, such as
children under the age of 5 years and pregnant
women, is a possible approach to the control of
malaria in areas of Africa where the infection is
endemic and where vector control is impossible. Mass
chemoprophylaxis, if properly administered, can
probably prevent deaths from malaria, but it favours
the emergence of drug-resistant parasites and it may
interfere with the development of natural immunity
to the infection. Critics of the concept of mass
chemoprophylaxis argue that there is little point in
protecting a child from malaria during the first 5
years of life if the child is likely to die from malaria
as soon as prophylaxis is stopped. Whether this is a
real or only a theoretical risk has never been clearly
established.
CLINICAL MALARIA AFTER A PERIOD
OF CHEMOPROPHYLAXIS
Repeated antigenic stimulation is required to
maintain established immunity to malaria and adult
Africans who return to an endemic area after a period
abroad may experience a clinical attack of the infec-
tion (1). However, such attacks are rarely severe,
even in individuals who have been away for many
years, indicating that a degree of immunity can be
preserved in the absence of exposure for a consider-
able period. Thus, it is unlikely that pregnant women
with established malaria immunity will lose this as
a result of taking chemoprophylaxis for only a few
months during pregnancy. In children, the situation
may be different.
Very few formal studies of the consequences of
stopping malaria chemoprophylaxis have been under-
taken in Africa. Pringle & Avery-Jones (2) reported
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that severe attacks of malaria occurred in Tanzanian
schoolchildren who had been protected from malaria
for only a few months by treatment with chloroquine
and primaquine. However, "rebound malaria" was
not observed in a group of Nigerian schoolchildren
when chemoprophylaxis with pyrimethamine was
stopped after a 1-2 year period of drug adminis-
tration (3). A group of 94 young Nigerian children
were carefully followed for 6 months after chemo-
prophylaxis was stopped (4). These children had
received chloroquine weekly from shortly after birth
until the age of 1 or 2 years. Only 1 death, for which
no cause could be established, occurred during the
follow-up period, which, for most children, covered
a rainy season. No increase in the incidence of severe
febrile illnesses was noted although morbidity was
not formally assessed in this study.
Some indications of the likely effects of mass
chemoprophylaxis on the development of immunity
to malaria can be obtained from study of projects in
which malaria control was successfully achieved for a
limited period by vector control or by vector control
combined with chemoprophylaxis. Unfortunately,
few studies were made of the impact on health of the
vector control programmes undertaken in tropical
Africa during the 1950s and 1960s. The control
scheme carried out in the Pare region of the United
Republic of Tanzania was an important exception.
In this area, malaria was effectively controlled for a
period of 3 years by spraying with dieldrin. Pringle
(5) studied what happened when malaria control was
stopped. The number of clinical cases of malaria in
the area and the prevalence of parasitaemia in school-
children increased about 1 year after the final round
of spraying (Fig. 1) and this increase persisted into
the following year. However, no increase in the
incidence of deaths from malaria was reported. At
Garki, in northern Nigeria, very effective malaria
control was achieved over a period of two rainy
4470 -69-
B. M. GREENWOOD
3.9.
266
a
4 12 1i 21 24
I- -X -3
23 32 -36
MONTHS
Fig. 1. Number of Tanzanian children aged 2-9 years with malaria parasitaemia at varying times between 6 and
36 months after interruption of a malaria control programme. (From Pringle (5)).
seasons by a combination of vector control and
chemoprophylaxis (6). Following the interruption of
control measures, the prevalence of malaria para-
sitaemia gradually rose to the pre-intervention level
(Fig. 2) and the prevalence of Plasmodium falci-
parum parasitaemia in previously protected subjects
over the age of 10 years temporarily exceeded the
level found in controls (Fig. 3). However, this effect
was not marked and it was not accompanied by any
increase in the incidence of febrile illnesses. Chloro-
quine was widely available in the study area during
the post-intervention period and this may have con-
tributed to the absence of such an increase.
CHEMOPROPHYLAXIS AND THE ANTIBODY
RESPONSE TO MALARIA
Few studies of the effects of chemoprophylaxis on
the antibody response to malaria have been under-
taken. Early studies by McGregor and his colleagues
(7- 9) showed that serum gamma-globulin levels
were lower in Gambian children and pregnant women
who received regular chemoprophylaxis than in con-
trols (Table 1). In children, a difference was present
between the two groups by the age of 2 years.
Voller & Wilson (10) measured malaria antibodies
by the fluorescent antibody technique in a small
number of Gambian infants and mothers who were
protected from malaria by weekly administration of
pyrimethamine. At a mean age of 7 months, fluor-
Table 1. Mean serum gamma-globulin levels (expressed
as a percentage of total serum protein) in Gambian
children maintained on chemoprophylaxis with chloro-
quine and in age-matched control children'
Protected children Control children
Age
(years) Number Mean Number Mean
1 27 19.7±4.7 29 19.7+4.1
2 22 20.6±3.9b 21 26.1±5.5
4 16 24.3±5.7b 13 32.2±4.4
5 21 23.9±3.1b 13 27.7±4.6
6 20 25.2±3.9b 1 1 31.4±3.5
Compiled from data from Gilles & McGregor (7) and from
McGregor & Gilles (8).
b Differences between groups statistically significant.
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Fig. 2. The prevalence of P. falciparum parasitaemia during the 1 970s at Garki (northern Nigeria) before, during,
and after a malaria control programme ("intervention phase"). (From Molineaux & Gramiccia (6)).
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Fig. 3. The prevalence of parasitaemia with asexual forms of P. falciparum, by age group, in Nigerians previously
protected from malaria for two wet seasons (P) and in unprotected controls (U). (From Molineaux & Gramiccia (6)).
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Table 2. The influence of weekly chemoprophylaxis with chloroquine, given for 1 or 2 years from shortly after
birth, on the development of malaria antibodies in Nigerian childrena
Protected children Control children
Antibody
measurement Age No. No. Percentage No. No. Percentage
technique (years) tested positive positive tested positive positive
Precipitin technique 1 21 10 48 11 10 91
2 23 18 78 22 20 91
ELISAb 1 42 13 31 39 26 67
2 53 36 68 54 50 93
Fluorescent antibody 1 10 9 90 8 8 100
techniqueC 2 10 7 70 15 15 100
a From Bradley-Moore (4 ).
b Sera giving an absorbance of 0.2 or greater were considered positive.
c Sera giving fluorescence at a titre of 1: 20 or greater were considered positive.
escent antibody was found in all of 7 control infants
but in none of 7 protected children. The mean fluor-
escent antibody titre found in pregnant women who
received chemoprophylaxis was about one third of
the mean titre found in control women. In Uganda,
fluorescent antibody was found in a higher propor-
tion of supposedly protected children (12 of 26) but
these children were older than the infants studied in
the Gambia (11). Ibeziako & Williams (12) found
low levels of fluorescent malaria antibody in a group
of pregnant Nigerian women who had been given
pyrimethamine throughout pregnancy but, as control
sera were not tested at the same time, these data are
difficult to interpret.
In the Malumfashi study (4), malaria antibody
levels were measured at intervals in children given
chloroquine weekly throughout the first 2 years of
life. Antibodies were measured by the fluorescent
antibody technique, enzyme-linked immunosorbent
assay (ELISA), and precipitin techniques. The find-
ings of this study are summarized in Table 2. Differ-
ences were found between the two groups but, by the
age of 2 years, a high proportion of children who had
received chemoprophylaxis had developed antibody.
The effects of chemoprophylaxis on the develop-
ment of malaria antibodies have been studied at the
community level by Onori et al. (13) who measured
malaria antibodies by the fluorescent antibody tech-
nique in 300 subjects from Mto-wa-Mbu in the United
Republic of Tanzania, where chloroquine has been
used widely for chemoprophylaxis for nearly 20 years.
Despite high levels of parasitaemia (average 47%),
only 67% of the population had fluorescent antibody
at a titre of 1: 20 or greater and mean titres were low
in subjects in each age group. Antibody was not de-
tected in sera from nearly one half of children with
parasitaemia. Unfortunately, no pre-intervention
data on antibody levels had been collected in this
Table 3. Prevalence of a positive fluorescent malaria antibody test by age in Muheza-Ubembe, United Republic
of Tanzania, in 1967 and in Mto-wa-Mbu in 1981°
Muheza-Ubembe, 1967 Mto-wa-Mbu, 1981 b
Age group No. of people Percentage Age group No. of people Percentage
(years) examined positive (years) examined positive
<1 25 71 <1 20 40
1 21 84 1 11 46
2-5 102 85 2-4 39 56
6-10 124 92 5-9 48 40
11-15 120 92 10-14 34 65
>16 403 98 )15 148 84
0 Based on data from Onori et al. (13 ).
bChemoprophylaxis with chloroquine has been practised in Mto-wa-Mbu for two decades. Prior to intervention the prevalence
of parasitaemia in the two communities was similar.
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population, but the antibody levels found in 1981 at
Mto-wa-Mbu were much lower than those recorded
previously in other parts of Tanzania where no
chemoprophylaxis had been given (Table 3). The
antigen used to measure antibodies in sera from
Mto-wa-Mbu was a Gambian isolate of P. falciparum
that had been kept in culture for many years. It is
possible that use of this strain, rather than a fresh
Tanzanian isolate, may have influenced the sero-
logical results obtained.
The most detailed information collected to date on
the influence of malaria control on the development
of malaria antibodies has come from the Garki study,
in which malaria control was achieved by a combin-
ation of insecticide spraying and chemoprophylaxis
(6). At Garki, malaria antibodies were measured by
the fluorescent antibody technique, indirect haemag-
glutination, and precipitin techniques, and serum im-
munoglobulin levels were determined by the Mancini
method. Serum IgM and malaria antibody levels fell
significantly following intervention. For IgM the dif-
ference between protected and control subjects was
most marked in adults, while differences in malaria
antibody levels were most marked in children. Very
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low malaria antibody levels were found in a group
of protected infants followed up from birth until the
age of 1 year (Fig. 4). During the 2-year period of
observation that followed interruption of malaria
control, immunoglobulin and malaria antibody levels
gradually increased and the level of haemagglutin-
ating P. falciparum antibody in the previously pro-
tected group temporarily exceeded the level found in
controls, an observation in keeping with the parasito-
logical changes found at this time.
CHEMOPROPHYLAXIS AND THE IMMUNE
RESPONSE TO IMMUNIZATION
The antibody response of children with acute
malaria to immunization with tetanus, typhoid, and
meningococcal vaccines is impaired (14-16) and this
generalized depression of humoral immunity may
contribute to the increased susceptibility of children
with malaria to secondary bacterial infections, such
as salmonellosis. Immunodepression induced by
malaria could also be one of the factors responsible
for the poor response to routine immunization some-
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Fig. 4. Titres of fluorescent antibodies to P. falciparum (mean and 95% confidence limits) in Nigerian infants
protected from malaria from birth and in control infants. (From Molineaux & Gramiccia (6)).
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Table 4. Seroconversion rates to routine immunization in
Nigerian children given weekly chemoprophylaxis with
chloroquine from birth and in age-matched controlsa
Protected childrenb Control childrenb
Proportion Proportion
who sero- who sero-
Vaccine converted % converted %
Diphtheria 134/135 99 127/130 98
Tetanus 134/135 99 127/128 99
Poliomyelitis
(type 1) 13/27 48 11/19 58
Measles 90/91 99 90/91 99
Meningococcal
group A 13/18 72 1 5/18 83
Meningococcal
group C 41 /48c 85 30/49 61
Typhoid 3/3 100 3/3 100
a From Bradley-Moore (4 ).
b Data are presented for children who did not have antibody
at the time of vaccination.
c p= 0.01.
times observed in communities where malaria is
endemic. This possibility was investigated in the
Malumfashi study in which the immune response to
a standard programme of infant immunization was
determined in a group of Nigerian infants who re-
ceived chemoprophylaxis with chloroquine from
shortly after birth and in a group of control children
(4-17). Significant differences between the two
groups were found only for meningococcal polysac-
charide vaccine (Table 4), a finding in keeping with
the observation that, in a malaria endemic area, the
immune response to this vaccine can be improved by
prior administration of chloroquine (18).
CONCLUSIONS
The limited number of studies that have been
undertaken so far show that control of malaria pro-
duces a fall in malaria antibody levels in the protected
population and that the magnitude of this fall is re-
lated to the efficacy of the control programme. Thus,
at Garki, where very effective malaria control was
achieved by a combination of insecticide spraying
and chemoprophylaxis, very low malaria antibody
levels were found in a group of infants protected from
birth. On the other hand, at Malumfashi, where less
effective malaria control was achieved, most pro-
tected children had malaria antibodies by the age of
2 years. The results of the Malumfashi study are
likely to be a closer reflection of what would happen
following the introduction of malaria chemoprophy-
laxis into a primary health care programme than the
results obtained at Garki.
None of the antibodies measured in standard sero-
logical tests is related to clinical immunity and it
would be of interest to know what influence chemo-
prophylaxis might have on the development of mero-
zoite-growth-inhibiting, opsonizing, and adherence-
inhibiting antibodies, each of which may have an
important biological function.
No properly controlled studies of the effects of
malaria chemoprophylaxis on the development of
protective immunity have been undertaken. It seems
unlikely that chemoprophylaxis could be given suf-
ficiently effectively at the community level to prevent
all episodes of parasitaemia and the consequent
development of some protective immunity. Whether
or not this is the case must be firmly established
before chemoprophylaxis is introduced widely into
primary health care programmes throughout Africa.
ACKNOWLEDGEMENT
The author is supported by the Medical Research Council of Great Britain.
RESUME
L'IMPACT DE LA CHIMIOPROPHYLAXIE DU PALUDISME SUR L'8TAT IMMUNITAIRE DES AFRICAINS
Les etudes, peu nombreuses, entreprises jusqu'ici in-
diquent que du fait de la lutte antipaludique, il se produit
une chute des taux d'anticorps antiplasmodies dans les
populations protegees et que l'importance de cette chute
est en rapport avec l'efficacite du programme de lutte.
Ainsi, a Garki, oui l'on est parvenu a lutter tres efficace-
ment contre le paludisme en combinant les pulverisations
d'insecticides et la chimioprophylaxie, on a trouve des taux
d'anticorps tres faibles dans un groupe de nourrissons pro-
teges depuis la naissance. D'autre part, a Malumfashi, oii
l'on n'a pas reussi a contenir aussi efficacement le palu-
disme, la majorite des enfants proteges possedaient encore
des anticorps a I'age de 2 ans. Les resultats de l'etude de
Malumfashi sont susceptibles d'etre plus representatifs que
ceux de Garki de l'impact que pourrait avoir la chimio-
prophylaxie antipaludique menee dans le cadre des soins de
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sante primaires.
L'un des anticorps titre selon les methodes serologiques
classiques est en rapport avec l'immunite clinique et il serait
interessant de savoir quelle influence la chimioprophylaxie
pourrait avoir sur I'apparition d'anticorps inhibant la crois-
sance des merozoites, d'opsonines et d'anticorps inhibiteurs
de I'adherence, chacun d'eux ayant une importante fonc-
tion biologique.
Aucune etude, convenablement contr6lee, des effets de la
chimioprophylaxie antipaludique sur le developpement de
l'immunoprotection n'a e realisee. II semble en tous cas
improbable que la chimioprophylaxie puisse etre adminis-
tree assez efficacement au niveau communautaire pour pre-
venir tous les episodes de parasitemie et emp&her, par
suite, l'apparition d'une immunoprotection. C'est 1a une
hypothese qu'il convient de confirmer avant d'introduire
largement la chimioprophylaxie dans les programmes de
soins de sante primaires dans toute l'Afrique.
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